# 20/20 Biolabs, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/20/20 Biolabs, Inc.). ## Overview 20/20 Biolabs, Inc. is a U.S.-based testing laboratory company that develops and sells diagnostic and screening products and also provides laboratory testing services. Its reported business includes OneTest, BioCheck, and CLIAx, with operations centered on regulated laboratory testing and related service work. ## Products & services • OneTest diagnostic/screening product • BioCheck testing product • CLIAx laboratory testing services • Third-party lab testing and compliance support - **OneTest** (88%) — A core testing product sold to customers that appears to be the company's main revenue driver. - **BioCheck** (6%) — A legacy testing product with declining relevance after patent expiration and increased competition. - **CLIAx** (6%) — Laboratory services performed under the company's CLIA-related testing operations. - OneTest diagnostic/screening product - BioCheck testing product - CLIAx laboratory testing services - Third-party lab testing and compliance support ## Customers The company sells to organizations and end users that need regulated testing, screening, and laboratory analysis. Reported disclosures point to fire department customers for OneTest and a CLIAx client for laboratory work, suggesting a mix of public-safety, institutional, and service-based demand. BioCheck appears to serve customers that value a specialized test product, though the product has faced competitive pressure over time. - **Fire departments and public-safety organizations** (primary) — They buy OneTest for testing needs tied to emergency-response or operational workflows. - **Laboratory services clients** (secondary) — They use CLIAx for outsourced testing and related lab services. - **Legacy BioCheck customers** (secondary) — They continue purchasing BioCheck where the product remains in use despite competitive and patent-related pressure. - Fire department customers buying OneTest for operational testing needs - Institutional or service clients using CLIAx laboratory work - Customers needing regulated diagnostic or screening products - Buyers seeking specialized testing with compliance support - Legacy BioCheck users that still require the product ## Geography 20/20 Biolabs is organized as a U.S. company and the available disclosures do not provide a country-by-country revenue split. Its business is tied to U.S. regulatory and laboratory requirements, which makes domestic compliance and customer access important to operations. The company also references the possibility of introducing and marketing products in other states or countries, but no specific foreign operating base is disclosed. - United States is the disclosed home market and operating base - Revenue geography is not broken out by country in the excerpts - Business depends on U.S. laboratory and regulatory compliance - Future expansion may involve additional states or countries - No authoritative regional revenue map was disclosed ## Strategy The company’s near-term focus is to support its testing and laboratory business with additional capital, while maintaining and commercializing its product and service lines. It also appears to be using public-market access and financing transactions to fund operations and growth initiatives. Product execution, customer renewals, and the ability to keep laboratory capacity utilized are central to its strategy. - **Strengthen capital access** (short-term) — The business needs external funding to support operations, commercialization, and working capital. - **Protect and grow core product sales** (short-term) — OneTest is the main revenue source and customer renewals materially affect quarterly results. - **Preserve laboratory service capability** (medium-term) — CLIAx and other lab work depend on fixed laboratory infrastructure and execution quality. - Raise capital to fund operations and product commercialization - Use public-market access to broaden financing options - Support OneTest sales and customer renewals - Maintain CLIAx laboratory utilization and service execution - Manage product development and intellectual property needs ## Risks The company faces concentration risk in a small number of products and customers, so timing shifts in renewals or work orders can materially affect quarterly revenue. It also has exposure to patent expiration, competition, regulatory compliance, and fixed laboratory cost absorption, which can pressure operating performance when volumes fall. Financing and dilution risk are also important because the business has relied on external capital to support operations. - **Customer concentration and renewal timing** [high] — A delayed renewal from a significant fire department customer materially affected OneTest revenue in the quarter. - **Product obsolescence and competition** [high] — BioCheck has been in long-term decline since patent expiration and the emergence of more direct competitors. - **Fixed-cost operating leverage** [medium] — Laboratory expenses include fixed costs that do not fall proportionally with test volume. - **Financing and dilution** [high] — The company has relied on equity, convertible notes, and warrants to fund operations. - **Regulatory compliance** [medium] — Testing laboratories must meet CLIA and other regulatory requirements that can affect operations and expansion. - Revenue depends heavily on OneTest and a small customer base - BioCheck faces patent-expiration and competition pressure - Fixed lab costs can hurt margins when test volumes decline - Regulatory and compliance requirements can delay or raise costs - Convertible financing and warrants can dilute shareholders ## Accounting Revenue recognition is important because the company sells products and also performs laboratory services, which may be recognized at different points in time depending on delivery and service completion. Quarterly results can be volatile because customer renewal timing and work timing shift revenue between periods, while fixed lab costs remain relatively stable. Investors should also watch fair value accounting for warrants and convertible instruments, as well as any estimates tied to debt issuance, derivative liabilities, and lease obligations. - **Revenue recognition for product sales and services** — Affects quarterly revenue timing and comparability - **Fair value of warrant liabilities** — Can create non-cash volatility in other income/expense - **Convertible note accounting** — Affects reported net loss and financing costs - **Fixed-cost absorption in laboratory operations** — Can distort gross margin when revenues decline - Product sales and lab services may follow different revenue timing - Quarterly revenue can shift with customer renewal and work timing - Fixed lab costs affect gross margin when volume changes - Warrant liability fair value can create non-cash gains or losses - Convertible notes can create issuance losses and interest expense --- *Last updated: 2026-08-11T04:46:16.712247+00:00*